Mycosis Fungoides and Sezary Syndrome: An Update.
Larocca C, Kupper T.
Hematol Oncol Clin North Am. 2019 Feb;33(1):103-120. doi: 10.1016/j.hoc.2018.09.001.
Mycosis Fungoides and Sezary Syndrome: Updates and Review of Current Therapy.
Kamijo H, Miyagaki T.
Curr Treat Options Oncol. 2021 Jan 7;22(2):10. doi: 10.1007/s11864-020-00809-w.
Sezary Syndrome, recent biomarkers and new drugs.
Cristofoletti C, Narducci MG, Russo G.
Chin Clin Oncol. 2019 Feb;8(1):2. doi: 10.21037/cco.2018.11.02. Epub 2018 Nov 28.
Sezary syndrome and mycosis fungoides flow cytometric evaluation: The clinicians' perspective.
Guitart J.
Cytometry B Clin Cytom. 2021 Mar;100(2):129-131. doi: 10.1002/cyto.b.21870. Epub 2020 Feb 4.
Sezary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping.
Pulitzer MP, Horna P, Almeida J.
Cytometry B Clin Cytom. 2021 Mar;100(2):132-138. doi: 10.1002/cyto.b.21888. Epub 2020 Jun 9.
Sezary syndrome-clinical and histopathologic features, differential diagnosis, and treatment.
Spicknall KE.
Semin Cutan Med Surg. 2018 Mar;37(1):18-23. doi: 10.12788/j.sder.2018.005.
Sezary Syndrome: Clinical and Biological Aspects.
Kohnken R, Fabbro S, Hastings J, Porcu P, Mishra A.
Curr Hematol Malig Rep. 2016 Dec;11(6):468-479. doi: 10.1007/s11899-016-0351-0.
Sezary syndrome: old enigmas, new targets.
Nicolay JP, Felcht M, Schledzewski K, Goerdt S, Géraud C.
J Dtsch Dermatol Ges. 2016 Mar;14(3):256-64. doi: 10.1111/ddg.12900.
Blood will tell: profiling Sezary syndrome.
Jonak C, Brunner PM.
Blood. 2021 Dec 16;138(24):2450-2451. doi: 10.1182/blood.2021013433.
Non-Classic Signs of Sezary Syndrome: A Review.
Morris L, Tran J, Duvic M.
Am J Clin Dermatol. 2020 Jun;21(3):383-391. doi: 10.1007/s40257-020-00501-7.
